Selected research
Industry Research
Infectious Vaccines Industry Research Report 2026
Market perspective
The global Infectious Vaccines market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Infectious Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Infectious Vaccines is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Infectious Vaccines is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Infectious Vaccines include Sanofi Pasteur (France), Johnson and Johnson (U.S.), Novartis AG (Switzerland), Merck and Company (U.S.), Pfizer Inc. (U.S.), GlaxoSmithKline plc. (U.K.), MedImmune LLC (U.S.), Emergent Bio Solutions Inc. (U.S.) and CSL Limited (Australia), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Infectious Vaccines market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Infectious Vaccines Market by Company
Sanofi Pasteur (France)
Johnson and Johnson (U.S.)
Novartis AG (Switzerland)
Merck and Company (U.S.)
Pfizer Inc. (U.S.)
GlaxoSmithKline plc. (U.K.)
MedImmune LLC (U.S.)
Emergent Bio Solutions Inc. (U.S.)
CSL Limited (Australia)
Bavarian Nordic (Denmark)
Infectious Vaccines Segment by Type
Preventive Vaccine
Therapeutic Vaccine
Infectious Vaccines Segment by Application
Adults
Pediatrics
Infectious Vaccines Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Infectious Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Infectious Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Infectious Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Infectious Vaccines manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Infectious Vaccines by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Infectious Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Preventive Vaccine
- Therapeutic Vaccine
Applications
- Adults
- Pediatrics
Companies covered
- Sanofi Pasteur (France)
- Johnson and Johnson (U.S.)
- Novartis AG (Switzerland)
- Merck and Company (U.S.)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc. (U.K.)
- MedImmune LLC (U.S.)
- Emergent Bio Solutions Inc. (U.S.)
- CSL Limited (Australia)
- Bavarian Nordic (Denmark)
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Infectious Vaccines Market Size (2021-2032)
- 2.2.2 Global Infectious Vaccines Sales (2021-2032)
- 2.2.3 Global Infectious Vaccines Market Average Price (2021-2032)
- 2.3 Infectious Vaccines by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Preventive Vaccine
- 2.3.3 Therapeutic Vaccine
- 2.4 Infectious Vaccines by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Adults
- 2.4.3 Pediatrics
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Infectious Vaccines Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Infectious Vaccines Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Infectious Vaccines Revenue of Manufacturers (2021-2026)
- 3.4 Global Infectious Vaccines Average Price by Manufacturers (2021-2026)
- 3.5 Global Infectious Vaccines Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Infectious Vaccines, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Infectious Vaccines, Product Type & Application
- 3.8 Global Manufacturers of Infectious Vaccines, Established Date
- 3.9 Global Infectious Vaccines Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Sanofi Pasteur (France)
- 4.1.1 Sanofi Pasteur (France) Company Information
- 4.1.2 Sanofi Pasteur (France) Business Overview
- 4.1.3 Sanofi Pasteur (France) Infectious Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Sanofi Pasteur (France) Infectious Vaccines Product Portfolio
- 4.1.5 Sanofi Pasteur (France) Recent Developments
- 4.2 Johnson and Johnson (U.S.)
- 4.2.1 Johnson and Johnson (U.S.) Company Information
- 4.2.2 Johnson and Johnson (U.S.) Business Overview
- 4.2.3 Johnson and Johnson (U.S.) Infectious Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Johnson and Johnson (U.S.) Infectious Vaccines Product Portfolio
- 4.2.5 Johnson and Johnson (U.S.) Recent Developments
- 4.3 Novartis AG (Switzerland)
- 4.3.1 Novartis AG (Switzerland) Company Information
- 4.3.2 Novartis AG (Switzerland) Business Overview
- 4.3.3 Novartis AG (Switzerland) Infectious Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Novartis AG (Switzerland) Infectious Vaccines Product Portfolio
- 4.3.5 Novartis AG (Switzerland) Recent Developments
- 4.4 Merck and Company (U.S.)
- 4.4.1 Merck and Company (U.S.) Company Information
- 4.4.2 Merck and Company (U.S.) Business Overview
- 4.4.3 Merck and Company (U.S.) Infectious Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Merck and Company (U.S.) Infectious Vaccines Product Portfolio
- 4.4.5 Merck and Company (U.S.) Recent Developments
- 4.5 Pfizer Inc. (U.S.)
- 4.5.1 Pfizer Inc. (U.S.) Company Information
- 4.5.2 Pfizer Inc. (U.S.) Business Overview
- 4.5.3 Pfizer Inc. (U.S.) Infectious Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Pfizer Inc. (U.S.) Infectious Vaccines Product Portfolio
- 4.5.5 Pfizer Inc. (U.S.) Recent Developments
- 4.6 GlaxoSmithKline plc. (U.K.)
- 4.6.1 GlaxoSmithKline plc. (U.K.) Company Information
- 4.6.2 GlaxoSmithKline plc. (U.K.) Business Overview
- 4.6.3 GlaxoSmithKline plc. (U.K.) Infectious Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 GlaxoSmithKline plc. (U.K.) Infectious Vaccines Product Portfolio
- 4.6.5 GlaxoSmithKline plc. (U.K.) Recent Developments
- 4.7 MedImmune LLC (U.S.)
- 4.7.1 MedImmune LLC (U.S.) Company Information
- 4.7.2 MedImmune LLC (U.S.) Business Overview
- 4.7.3 MedImmune LLC (U.S.) Infectious Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 MedImmune LLC (U.S.) Infectious Vaccines Product Portfolio
- 4.7.5 MedImmune LLC (U.S.) Recent Developments
- 4.8 Emergent Bio Solutions Inc. (U.S.)
- 4.8.1 Emergent Bio Solutions Inc. (U.S.) Company Information
- 4.8.2 Emergent Bio Solutions Inc. (U.S.) Business Overview
- 4.8.3 Emergent Bio Solutions Inc. (U.S.) Infectious Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Emergent Bio Solutions Inc. (U.S.) Infectious Vaccines Product Portfolio
- 4.8.5 Emergent Bio Solutions Inc. (U.S.) Recent Developments
- 4.9 CSL Limited (Australia)
- 4.9.1 CSL Limited (Australia) Company Information
- 4.9.2 CSL Limited (Australia) Business Overview
- 4.9.3 CSL Limited (Australia) Infectious Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 CSL Limited (Australia) Infectious Vaccines Product Portfolio
- 4.9.5 CSL Limited (Australia) Recent Developments
- 4.10 Bavarian Nordic (Denmark)
- 4.10.1 Bavarian Nordic (Denmark) Company Information
- 4.10.2 Bavarian Nordic (Denmark) Business Overview
- 4.10.3 Bavarian Nordic (Denmark) Infectious Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Bavarian Nordic (Denmark) Infectious Vaccines Product Portfolio
- 4.10.5 Bavarian Nordic (Denmark) Recent Developments
5 Global Infectious Vaccines Market Scenario by Region
- 5.1 Global Infectious Vaccines Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Infectious Vaccines Sales by Region: 2021-2032
- 5.2.1 Global Infectious Vaccines Sales by Region: 2021-2026
- 5.2.2 Global Infectious Vaccines Sales by Region: 2027-2032
- 5.3 Global Infectious Vaccines Revenue by Region: 2021-2032
- 5.3.1 Global Infectious Vaccines Revenue by Region: 2021-2026
- 5.3.2 Global Infectious Vaccines Revenue by Region: 2027-2032
- 5.4 North America Infectious Vaccines Market Facts & Figures by Country
- 5.4.1 North America Infectious Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Infectious Vaccines Sales by Country (2021-2032)
- 5.4.3 North America Infectious Vaccines Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Infectious Vaccines Market Facts & Figures by Country
- 5.5.1 Europe Infectious Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Infectious Vaccines Sales by Country (2021-2032)
- 5.5.3 Europe Infectious Vaccines Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Infectious Vaccines Market Facts & Figures by Country
- 5.6.1 Asia Pacific Infectious Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Infectious Vaccines Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Infectious Vaccines Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Infectious Vaccines Market Facts & Figures by Country
- 5.7.1 South America Infectious Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Infectious Vaccines Sales by Country (2021-2032)
- 5.7.3 South America Infectious Vaccines Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Infectious Vaccines Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Infectious Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Infectious Vaccines Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Infectious Vaccines Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Infectious Vaccines Sales by Type (2021-2032)
- 6.1.1 Global Infectious Vaccines Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Infectious Vaccines Sales Market Share by Type (2021-2032)
- 6.2 Global Infectious Vaccines Revenue by Type (2021-2032)
- 6.2.1 Global Infectious Vaccines Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Infectious Vaccines Revenue Market Share by Type (2021-2032)
- 6.3 Global Infectious Vaccines Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Infectious Vaccines Sales by Application (2021-2032)
- 7.1.1 Global Infectious Vaccines Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Infectious Vaccines Sales Market Share by Application (2021-2032)
- 7.2 Global Infectious Vaccines Revenue by Application (2021-2032)
- 7.2.1 Global Infectious Vaccines Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Infectious Vaccines Revenue Market Share by Application (2021-2032)
- 7.3 Global Infectious Vaccines Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Infectious Vaccines Value Chain Analysis
- 8.1.1 Infectious Vaccines Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Infectious Vaccines Production Mode & Process
- 8.2 Infectious Vaccines Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Infectious Vaccines Distributors
- 8.2.3 Infectious Vaccines Customers
9 Global Infectious Vaccines Analyzing Market Dynamics
- 9.1 Infectious Vaccines Industry Trends
- 9.2 Infectious Vaccines Industry Drivers
- 9.3 Infectious Vaccines Industry Opportunities and Challenges
- 9.4 Infectious Vaccines Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst